Gelteq Limited
GELSHealthcareNASDAQDrug Manufacturers - Specialty & Generic
Scan Results
Daily timeframeGelteq Limited focuses on developing and commercializing white label gel-based delivery solutions for humans and animals in the United States of America, China and Australia. At a $7.2M market cap, Gelteq Limited ranks as a micro-cap company within healthcare. It offers edible gels for prescription drugs, nutraceuticals, pet care, and other products, as well as for sports and over-the-counter products.
Market Cap
$7.2M
Beta
—
P/E (TTM)
—
P/E (Fwd)
—
EPS (TTM)
$-0.52
EPS (Fwd)
—
ROE
-42.9%
ROA
-17.6%
Cash
$9,349
Total Debt
$5.1M
Free CF
-$4.8M
52W Change
-33.3%
Annual Financials
Cash vs Debt
Where GELS stands vs its 150-day and 200-day moving averages
As of the August 14, 2026 close, GELS finished 17.14% below its 150-day moving average ($0.70) and 25.64% below its 200-day moving average ($0.78). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is GELS overbought or oversold?
At the August 14, 2026 close, GELS's RSI(14) was 30.9, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The company holds $9K in cash, though total debt stands at $5.1M. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. Free cash flow is running at -$4.8M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -42.9%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has been uneven over recent years, ranging from $148K to $166K.
The debt-to-cash ratio suggests meaningful leverage on the balance sheet, a factor worth monitoring if credit conditions tighten. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Gelteq Limited's trajectory.